Imperial Innovations supports NanoBioDesign
Imperial Innovations, the technology commercialisation company of Imperial College London, has completed its first investment in a biotech company since its private placement in April 2005. The company has invested into Imperial spin-out, NanoBioDesign, an organisation developing a range of screening systems to speed up the drug discovery process.
More on Early-stage
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
French mega-rounds shoot up in 2021
France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows
L Catterton et al. in EUR 100m round for SellerX
SellerX has already raised amost EUR 250m in debt and equity in its 12 months since inception
Mega-rounds fuel record H1 for venture and growth
Largest rounds inked in the first six months of 2021 read like a veritable Who's Who of European fintech heavyweights
Latest News
Gyrus buys majority stake in Katalist Group
GP and Katalist's founders are planning bolt-ons for the food and pharma supply chain software firm
Bain Capital, Nextalia to acquire Deltatre from Bruin Sports Capital
Italian sports technology provider first sale attempt was hampered by the onset of COVID-19 in early 2020
FirstAvenue appoints Chronias as capital solutions group head
Nick Chronias will lead the firm’s focus on private credit and private infrastructure secondaries
Riverside appoints Höppner as chief sustainability officer
Dörte Höppner joined the GP in 2017 and will be responsible for its ESG initiatives globally